<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00421720</url>
  </required_header>
  <id_info>
    <org_study_id>USA107212</org_study_id>
    <secondary_id>EudraCT: 2006-001276-20</secondary_id>
    <nct_id>NCT00421720</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Analgesia/Sedation Regimens, Remifentanil/Propofol Versus Sufentanil/Propofol In Mechanically Ventilated Intensive Care Patients Requiring Analgesia And Sedation.</brief_title>
  <official_title>A Randomized, Open-label, Multicenter, Parallel-group Study to Compare the Efficacy, Safety and Resource Utilization of a Remifentanil/Propofol Analgesia/Sedation Regimen Versus a Sufentanil/Propofol Analgesia/Sedation Regimen in Mechanically Ventilated Intensive Care Patients Requiring Analgesia and Sedation for up to 7 Days</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      This prospective, randomized, multicenter, open-label study will compare two analgesia-based&#xD;
      regimens for sedation (remifentanil/propofol vs. sufentanil/propofol) in medium to long-term&#xD;
      ventilated intensive care patients in terms of efficacy, safety and resource utilization.&#xD;
&#xD;
      The special characteristics of intensive care patients (organ insufficiencies etc.) regularly&#xD;
      cause an accumulation of the analgesics, sedatives and adjuvants used. Clinically, this&#xD;
      complicates the calculation of weaning and extubation times, often making mechanical&#xD;
      ventilation necessary for longer periods than desired and also extending the stay of patients&#xD;
      in the intensive care unit. Reducing weaning times and the duration of intensive care&#xD;
      treatment by optimizing analgesia/sedation could furthermore lead to a reduction in typical&#xD;
      complications such as ventilator-associated pneumonia or delirium.&#xD;
&#xD;
      The demands on an ideal analgesic are analgesic efficacy without severe cardiopulmonary&#xD;
      depression and rapid onset of effect and in particular a short dura-tion of effect and&#xD;
      absence of accumulation or development of active metabolites. Remifentanil is an ultra-short&#xD;
      acting µ-agonist which is, due to its molecular structure, metabolized organ-independently by&#xD;
      unspecific blood and tissue esterases with the substance being degraded within only a few&#xD;
      minutes and the resulting metabolites being virtually ineffective at the µ-receptor.&#xD;
      Sufentanil, on the other hand, is mainly metabolized by the cytochrome P-450-3A4 enzyme in&#xD;
      the liver and small intestine.&#xD;
&#xD;
      To date, only one study with a small sample size is available on the comparison of the&#xD;
      effectiveness and safety of remifentanil and sufentanil when used for long-term&#xD;
      analgesia/sedation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>January 2007</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of ventilation and weaning times: - Time from initiation of analgesia/sedation using the investigational substance and extubation (&quot;ventilation time&quot;) - Time from the start of weaning to extubation (&quot;weaning time&quot;)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay; accuracy of analgesia/sedation; drug consumption of analgesics/sedatives; clinical course; incidence of pneumonia/delirium; infection markers; bowel movement; ventilation parameters; vital signs; resource utilization; safety</measure>
  </secondary_outcome>
  <enrollment>164</enrollment>
  <condition>Analgesia</condition>
  <condition>Sedation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sufentanil</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
          -  Written informed consent was obtained from the patient&#xD;
&#xD;
          -  The patient is under intensive medical care, intubated and ventilated&#xD;
&#xD;
          -  The expected duration of ventilation and analgesia/sedation is &gt; 24 hours and &lt;/= 7&#xD;
             days&#xD;
&#xD;
          -  Propofol is planned to be used as sedative&#xD;
&#xD;
        EXCLUSION CRITERIA&#xD;
&#xD;
          -  Contraindication against administration of remifentanil, sufentanil, or propofol&#xD;
&#xD;
          -  Concomitant medications:&#xD;
&#xD;
          -  The patient is receiving epidural analgesia or a peripheral regional anesthetic&#xD;
             therapy.&#xD;
&#xD;
          -  The patient is requiring muscle relaxants to facilitate mechanical ventilation&#xD;
&#xD;
          -  The patient participated in clinical drug trials within the previous 30 days or&#xD;
             participated in this clinical trial before or is currently participating in any other&#xD;
             clinical trial&#xD;
&#xD;
          -  The patient has a known hypersensitivity to the drugs under investigation or to&#xD;
             propofol (and other components of the preparation to be used), soy and peanut&#xD;
&#xD;
          -  For female patients: the patient is pregnant or breastfeeding&#xD;
&#xD;
          -  The patient is classified as ASA V or moribund&#xD;
&#xD;
          -  The patient must be expected to show an impaired cerebral or neurologic capacity due&#xD;
             to illness, trauma or other interventions, which will interfere with the collection of&#xD;
             the analgesia/sedation scores and the waking behavior as for example, without being&#xD;
             limited to:&#xD;
&#xD;
          -  Hypoxic brain damage&#xD;
&#xD;
          -  Cerebrocranial trauma grades II, III, and IV&#xD;
&#xD;
          -  Subarachnoid hemorrhage, brain-stem hemorrhage, ischemic-hemorrhagic cerebral&#xD;
             hemorrhages&#xD;
&#xD;
          -  Amyotrophic lateral sclerosis, myasthenia gravis&#xD;
&#xD;
          -  Stupor or coma&#xD;
&#xD;
          -  The patient requires chronic ventilation&#xD;
&#xD;
          -  The patient is receiving chronic (&gt; 3 months) therapy with high-potency opioids/WHO&#xD;
             level 3&#xD;
&#xD;
          -  The patient is alcohol or drug dependent (legal or illegal drugs in particular, but&#xD;
             not exclusively with dependency on sedatives or benzodiazepines), defined as:&#xD;
&#xD;
          -  Typically an urgent desire to take the substance, problems in controlling consumption,&#xD;
             and persistent use of the substance despite adverse consequences. The use of the&#xD;
             substance has priority over other activities and responsibilities. Developing&#xD;
             increased tolerance and occasionally physical withdrawal symptom.&#xD;
&#xD;
          -  The patient suffers from a manifest organ failure&#xD;
&#xD;
          -  The patient suffers from severe heart failure, NYHA Class IV (symptoms at rest)&#xD;
&#xD;
          -  The patient has a history of or actually suffers from ventricular tachycardia,&#xD;
             ventricular flutter or ventricular fibrillation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Rostock</city>
        <zip>18057</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Saarbrucken</city>
        <zip>66119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Schwerin</city>
        <zip>19049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Clinical Trials Call Center</name>
      <address>
        <city>Tubingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <study_first_submitted>January 11, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2007</study_first_posted>
  <last_update_submitted>March 30, 2018</last_update_submitted>
  <last_update_submitted_qc>March 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>remifentanil</keyword>
  <keyword>sufentanil</keyword>
  <keyword>propofol</keyword>
  <keyword>analgesia</keyword>
  <keyword>sedation</keyword>
  <keyword>mechanically ventilated</keyword>
  <keyword>intensive care</keyword>
  <keyword>pharmacoeconomic</keyword>
  <keyword>weaning</keyword>
  <keyword>delirium</keyword>
  <keyword>randomized</keyword>
  <keyword>Germany</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Agnosia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sufentanil</mesh_term>
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

